These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 24606436)

  • 61. Hypomethylation of the synuclein gamma gene CpG island promotes its aberrant expression in breast carcinoma and ovarian carcinoma.
    Gupta A; Godwin AK; Vanderveer L; Lu A; Liu J
    Cancer Res; 2003 Feb; 63(3):664-73. PubMed ID: 12566312
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Cytoplasmic RASSF2A is a proapoptotic mediator whose expression is epigenetically silenced in gastric cancer.
    Maruyama R; Akino K; Toyota M; Suzuki H; Imai T; Ohe-Toyota M; Yamamoto E; Nojima M; Fujikane T; Sasaki Y; Yamashita T; Watanabe Y; Hiratsuka H; Hirata K; Itoh F; Imai K; Shinomura Y; Tokino T
    Carcinogenesis; 2008 Jul; 29(7):1312-8. PubMed ID: 18310659
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Epithelial protein lost in neoplasm-α (EPLIN-α) is a potential prognostic marker for the progression of epithelial ovarian cancer.
    Liu R; Martin TA; Jordan NJ; Ruge F; Ye L; Jiang WG
    Int J Oncol; 2016 Jun; 48(6):2488-96. PubMed ID: 27035883
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Aberrant promoter methylation of the RASSF1A and APC genes in epithelial ovarian carcinoma development.
    Bhagat R; Chadaga S; Premalata CS; Ramesh G; Ramesh C; Pallavi VR; Krishnamoorthy L
    Cell Oncol (Dordr); 2012 Dec; 35(6):473-9. PubMed ID: 23055343
    [TBL] [Abstract][Full Text] [Related]  

  • 65. RUNX3 and CAMK2N1 hypermethylation as prognostic marker for epithelial ovarian cancer.
    Häfner N; Steinbach D; Jansen L; Diebolder H; Dürst M; Runnebaum IB
    Int J Cancer; 2016 Jan; 138(1):217-28. PubMed ID: 26175272
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Hypermethylation of the PTEN gene in ovarian cancer cell lines.
    Schöndorf T; Ebert MP; Hoffmann J; Becker M; Moser N; Pur S; Göhring UJ; Weisshaar MP
    Cancer Lett; 2004 Apr; 207(2):215-20. PubMed ID: 15072831
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Promoter methylation status and expression of TMS1 gene in human epithelial ovarian cancer.
    Akahira J; Sugihashi Y; Ito K; Niikura H; Okamura K; Yaegashi N
    Cancer Sci; 2004 Jan; 95(1):40-3. PubMed ID: 14720325
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Methylation-associated silencing of the Wnt antagonist SFRP1 gene in human ovarian cancers.
    Takada T; Yagi Y; Maekita T; Imura M; Nakagawa S; Tsao SW; Miyamoto K; Yoshino O; Yasugi T; Taketani Y; Ushijima T
    Cancer Sci; 2004 Sep; 95(9):741-4. PubMed ID: 15471560
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Aberrant hypermethylation of RASSF1A promoter in ovarian borderline tumors and carcinomas.
    Choi YL; Kang SY; Shin YK; Choi JS; Kim SH; Lee SJ; Bae DS; Ahn G
    Virchows Arch; 2006 Mar; 448(3):331-6. PubMed ID: 16315018
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Aberrant promoter methylation of SPARC in ovarian cancer.
    Socha MJ; Said N; Dai Y; Kwong J; Ramalingam P; Trieu V; Desai N; Mok SC; Motamed K
    Neoplasia; 2009 Feb; 11(2):126-35. PubMed ID: 19177197
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Methylation decreases the Bin1 tumor suppressor in ESCC and restoration by decitabine inhibits the epithelial mesenchymal transition.
    Wang X; Wang J; Jia Y; Wang Y; Han X; Duan Y; Lv W; Ma M; Liu L
    Oncotarget; 2017 Mar; 8(12):19661-19673. PubMed ID: 28152502
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Clinicopathological implications of inactivation of RASSF1A in serous epithelial ovarian cancers.
    Ma L; Guo Q; Ma Y; Liu FR; Shen XY
    Eur J Gynaecol Oncol; 2009; 30(4):370-4. PubMed ID: 19761124
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Aberrant hypermethylation of the HOXD10 gene in papillary thyroid cancer with BRAFV600E mutation.
    Cao YM; Gu J; Zhang YS; Wei WJ; Qu N; Wen D; Liao T; Shi RL; Zhang L; Ji QH; Wang Y; Sun GH; Zhao YX; Wang YJ; Yu J; Zhu YX
    Oncol Rep; 2018 Jan; 39(1):338-348. PubMed ID: 29115628
    [TBL] [Abstract][Full Text] [Related]  

  • 74. MicroRNA-145 targets TRIM2 and exerts tumor-suppressing functions in epithelial ovarian cancer.
    Chen X; Dong C; Law PT; Chan MT; Su Z; Wang S; Wu WK; Xu H
    Gynecol Oncol; 2015 Dec; 139(3):513-9. PubMed ID: 26472353
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Quantitative detection of RASSF1A DNA promoter methylation in tumors and serum of patients with serous epithelial ovarian cancer.
    Bondurant AE; Huang Z; Whitaker RS; Simel LR; Berchuck A; Murphy SK
    Gynecol Oncol; 2011 Dec; 123(3):581-7. PubMed ID: 21955482
    [TBL] [Abstract][Full Text] [Related]  

  • 76. [Disfigurement of p16INK4A gene expression in development of ovarian cancer and the mechanism].
    Li M; Huang ZJ; Dong WH; Li XY; Wang XY; He XH; Wang H; Wang ZH
    Zhonghua Fu Chan Ke Za Zhi; 2006 Jun; 41(6):408-12. PubMed ID: 16831366
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Aberrant methylation of APC, MGMT, RASSF2A, and Wif-1 genes in plasma as a biomarker for early detection of colorectal cancer.
    Lee BB; Lee EJ; Jung EH; Chun HK; Chang DK; Song SY; Park J; Kim DH
    Clin Cancer Res; 2009 Oct; 15(19):6185-91. PubMed ID: 19773381
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Loss of estrogen receptor beta isoform expression and its correlation with aberrant DNA methylation of the 5'-untranslated region in human epithelial ovarian carcinoma.
    Suzuki F; Akahira J; Miura I; Suzuki T; Ito K; Hayashi S; Sasano H; Yaegashi N
    Cancer Sci; 2008 Dec; 99(12):2365-72. PubMed ID: 19032364
    [TBL] [Abstract][Full Text] [Related]  

  • 79. miR-211 suppresses epithelial ovarian cancer proliferation and cell-cycle progression by targeting Cyclin D1 and CDK6.
    Xia B; Yang S; Liu T; Lou G
    Mol Cancer; 2015 Mar; 14():57. PubMed ID: 25889927
    [TBL] [Abstract][Full Text] [Related]  

  • 80. MicroRNA-130b functions as a tumor suppressor by regulating RUNX3 in epithelial ovarian cancer.
    Paudel D; Zhou W; Ouyang Y; Dong S; Huang Q; Giri R; Wang J; Tong X
    Gene; 2016 Jul; 586(1):48-55. PubMed ID: 27048832
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.